From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies.
From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies.
复制标题
从 CAR-T 细胞到 CAR-NK 细胞：一种正在开发的血液恶性肿瘤免疫治疗方法。
DOI：
10.3389/fonc.2021.720501
复制
发表时间：
2021
影响因子：
4.7
通讯作者：
Wang H
中科院分区：
文献类型：
--
作者：
Lu H;Zhao X;Li Z;Hu Y;Wang H
CD 19嵌合抗原受体（CAR）工程化T（CAR-T）细胞产品在B细胞恶性肿瘤中的批准代表了CAR-T细胞免疫治疗的突破。然而，关于移植物抗宿主病（GVHD）和其他不良反应（例如，细胞因子释放综合征[CRS]和神经毒性）仍然限制了它们的更广泛应用。自然杀伤（NK）细胞由于其独特的特性已被确定为基于CAR的细胞免疫疗法的有希望的候选者。无HLA匹配限制和丰富的来源使CAR工程化NK（CAR-NK）细胞可能成为现成的产品，可随时用于临床。因此，研究人员逐渐将关注点从CAR-T细胞转移到血液恶性肿瘤中的CAR-NK细胞。本文就CAR-NK细胞在血液系统恶性肿瘤中的应用现状以及CAR-NK细胞相对于CAR-T细胞的独特优势进行综述。它还讨论了CAR-NK细胞临床应用的挑战和前景。
The approval of CD19 chimeric antigen receptor (CAR)-engineered T (CAR-T) cell products in B-cell malignancies represents a breakthrough in CAR-T cell immunotherapy. However, the remaining limitations concerning the graft-versus-host disease (GVHD) and other adverse effects (e.g., cytokine release syndromes [CRS] and neurotoxicity) still restrict their wider applications. Natural killer (NK) cells have been identified as promising candidates for CAR-based cellular immunotherapy because of their unique characteristics. No HLA-matching restriction and abundant sources make CAR-engineered NK (CAR-NK) cells potentially available to be off-the-shelf products that could be readily available for immediate clinical use. Therefore, researchers have gradually shifted their focus from CAR-T cells to CAR-NK cells in hematological malignancies. This review discusses the current status and applications of CAR-NK cells in hematological malignancies, as well as the unique advantages of CAR-NK cells compared with CAR-T cells. It also discusses challenges and prospects regarding clinical applications of CAR-NK cells.
登录
查看更多内容
影响因子：
28.2
作者：
通讯作者：
--
影响因子：
11.4
作者：
Chen KH;Wada M;Pinz KG;Liu H;Lin KW;Jares A;Firor AE;Shuai X;Salman H;Golightly M;Lan F;Senzel L;Leung EL;Jiang X;Ma Y
通讯作者：
Ma Y
影响因子：
10.1
作者：
Chu, Yaya;Hochberg, Jessica;Cairo, Mitchell S.
通讯作者：
Cairo, Mitchell S.
影响因子：
20.3
作者：
Curti, Antonio;Ruggeri, Loredana;Lemoli, Roberto M.
通讯作者：
Lemoli, Roberto M.
影响因子：
7.2
作者：
Chu, Yaya;Yahr, Ashlin;Cairo, Mitchell S.
通讯作者：
Cairo, Mitchell S.